...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neurologia medico-chirurgica. >CyberKnife Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy As First-line Treatments for Imaging-diagnosed Intracranial Meningiomas
【24h】

CyberKnife Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy As First-line Treatments for Imaging-diagnosed Intracranial Meningiomas

机译：Cyber​​ Knife立体定向放射外科和低分离的立体定向放疗作为成像诊断的颅内脑膜瘤的一线治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Definitive radiotherapy is an important alternative treatment for meningioma patients who are inoperable or refuse surgery. We evaluated the efficacy and toxicity of CyberKnife-based stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (hSRT) as first-line treatments for intracranial meningiomas that were diagnosed using magnetic resonance imaging (MRI) and/or computed tomography (CT). Between February 2005 and September 2015, 41 patients with intracranial meningiomas were treated with CyberKnife-based SRS or hSRT. Eleven of those tumors were located in the skull base. The median tumor volume was 10.4 ml (range, 1.4–56.9 ml). The median prescribed radiation dose was 17 Gy (range, 13–20 Gy to the 61–88% isodose line) for SRS ( n = 9) and 25 Gy (range, 14–38 Gy to the 44–83% isodose line) for hSRT ( n = 32). The hSRT doses were delivered in 2 to 10 daily fractions. The median follow-up period was 49 months (range, 7–138). The 5-year progression-free survival rate (PFS) for all 41 patients was 86%. The 3-year PFS was 69% for the 14 patients with tumor volumes of ≥13.5 ml (30 mm in diameter) and 100% for the 27 patients with tumor volumes of 2 toxicities were observed in 5 patients (all of them had tumor volumes of ≥13.5 ml). SRS and hSRT are safe and effective against relatively small (
机译：明确的放射疗法是脑膜瘤患者的重要替代治疗，其无法操作或拒绝手术。我们评估了基于Cyber​​ Knife的立体定向放射牢（SRS）和低次定位的立体定向放射疗法（HSRT）作为使用磁共振成像（MRI）和/或计算机断层扫描（CT）的颅内脑膜瘤的一线治疗的疗效和毒性。 2005年2月至2015年9月期间，41例颅内脑膜瘤患者用基于Cyber​​ Knife的SRS或HSRT治疗。 11种肿瘤位于颅底。中位肿瘤体积为10.4ml（范围，1.4-56.9ml）。中位数规定的辐射剂量为17 gy（范围，13-20 gy至61-88％同学线），用于Srs（n = 9）和25 gy（范围，14-38 gy至44-83％的同学线）对于HSRT（n = 32）。 HSRT剂量在2至10个每日馏分中递送。中位后续期间为49个月（范围，7-138）。所有41名患者的5年的无进展生存率（PFS）为86％。对于14例肿瘤体积≥13.5毫升（直径为30毫米）的患者，3年的PFS为69％，在5名患者中观察到27例肿瘤体积的27例肿瘤体积患者（所有患有肿瘤体积） ≥13.5毫升）。 SRS和HSRT对比较小的安全有效（

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号